HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rinne, U. K. Search for Related Content PubMed PubMed Citation Articles by Rinne, U. K.

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease

A 5-year follow-up

Department of Neurology, University of Turku, Turku, Finland.

Compared with levodopa, long-term bromocriptine treatment of parkinsonian patients for 5 years resulted in fewer fluctuations of disability and peak-dose dyskinesias, but also less improvement in parkinsonian disability. Combination of low-dose bromocriptine and levodopa resulted in a therapeutic response equal to that of levodopa alone but with fewer end-of-dose disturbances and peak-dose dyskinesias. I believe that treatment should begin promptly with a low dose of levodopa, combined with a dopamine agonist such as bromocriptine.

Address correspondence and reprint requests to Dr. Rinne, Department of Neurology, University of Turk, SF-20520 Turku, Finland.

Presented in part at the thirty-eight annual meeting of the American Academy of Neurology, New Orleans, LA, April 1986.

Received May 7, 1986. Accepted for publication in final form August 27, 1986.

This article has been cited by other articles:

				A. Albanese Initial bromocriptine did not change mortality in early, mild Parkinson's disease Evid. Based Med., May 1, 2002; 7(3): 91 - 91. [Full Text] [PDF]

				C. W. Olanow The role of dopamine agonists in the treatment of early Parkinson's disease Neurology, February 1, 2002; 58(90001): S33 - 41. [Abstract] [Full Text]

				C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]

				A. Schrag and N. Quinn Dyskinesias and motor fluctuations in Parkinson's disease: A community-based study Brain, November 1, 2000; 123(11): 2297 - 2305. [Abstract] [Full Text] [PDF]

				P. Barone, D. Bravi, F. Bermejo-Pareja, R. Marconi, J. Kulisevsky, S. Malagu, R. Weiser, and N. Rost Pergolide monotherapy in the treatment of early PD: A randomized, controlled study Neurology, August 1, 1999; 53(3): 573 - 573. [Abstract] [Full Text]

				A. D. Korczyn, E. R. Brunt, J. P. Larsen, Z. Nagy, W. H. Poewe, and S. Ruggieri A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease Neurology, July 1, 1999; 53(2): 364 - 364. [Abstract] [Full Text] [PDF]

				Developments in the treatment of Parkinson's disease DTB, May 1, 1999; 37(5): 36 - 40. [Abstract] [Full Text] [PDF]

				S. Fahn Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial Arch Neurol, May 1, 1999; 56(5): 529 - 535. [Full Text] [PDF]

				N. Quinn Fortnightly Review: Drug treatment of Parkinson's disease BMJ, March 4, 1995; 310(6979): 575 - 579. [Abstract] [Full Text]